A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Ontology highlight
ABSTRACT: This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.
DISEASE(S): Glioma,Melanoma,Mesothelioma,Retinoblastoma,Solid Tumors With Ptch1 Loss-of-function Mutations,Neoplasms
PROVIDER: 2401586 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA